Gina Kolata, a medical reporter for The New York Times, shares insights on sickle cell anemia's latest gene therapy developments. Deb Cromer discusses her son Kendrick's inspiring journey as the first to receive this treatment. They explore the emotional and logistical challenges families face, particularly regarding access to this groundbreaking therapy. The conversation highlights hopes for a potential cure while addressing systemic barriers and the importance of awareness in the journey to understanding this condition.
The gene therapy for sickle cell anemia represents a major medical advancement but is accompanied by high costs and accessibility challenges for families.
The emotional journey of Kendrick Cromer's parents highlights the resilience required to navigate the complexities of a debilitating disease and its treatments.
Deep dives
Understanding Sickle Cell Anemia
Sickle cell anemia is a genetic disorder that affects over 20 million people globally, with a significant prevalence among the Black community in the U.S. It is characterized by the transformation of healthy red blood cells into sharp, crescent-shaped cells that lead to severe pain and blockages in blood flow. Deb and Keith Cromer, parents of Kendrick, recount their emotional journey upon discovering their son had this condition just weeks after his birth. Despite the devastating news and the hardships that followed, including numerous missed school days due to pain crises, the family’s resilience and hope have shone through.
Breakthrough Gene Therapy
Recent advancements in medical treatments have introduced gene therapy as a potential cure for sickle cell anemia, with Kendrick being the first to undergo this FDA-approved procedure. This therapy involves complex steps, including the extraction and modification of stem cells from patients, followed by chemotherapy. Kendrick’s path to treatment was punctuated by urgent medical decisions, leading to the gene therapy just as his condition was worsening. While the process was initially daunting, it offered the promise of a better future free from the debilitating symptoms that had characterized Kendrick's childhood.
Challenges in Accessing Treatment
Despite gene therapy being available, significant hurdles remain in accessing this treatment for many patients suffering from sickle cell anemia. The costs associated with the therapy, which can exceed $3 million, combined with insurance compatibility issues, limit who can receive this potentially life-changing procedure. Many families face uncertainty regarding eligibility, compounded by state-by-state variations in Medicaid coverage. This disparity underscores the critical need for broader access to not only the therapy itself but also the necessary support and education surrounding sickle cell disease.
Last May, a 12-year-old with sickle cell anemia was the first person to receive a new gene therapy to treat the disease. The process is painful, expensive, and still frightening and uncertain, but biomedical researchers are cautiously calling it a “cure.”
Guests:
Gina Kolata, medical reporter for the New York Times
Deb and Keith Cromer, parents to Kendric Cromer, the first person in the world to go through a commercially approved gene therapy for sickle cell anemia.
Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.
Podcast production by Evan Campbell, Patrick Fort, and Cheyna Roth.